Stevens & Bolton has advised the shareholders and management team on the sale of Synchrony Pharma Ltd to CNX Therapeutics Ltd, a speciality pharmaceutical company with a focus on improving access to medicines.
Founded in 2008, Synchrony Pharma focuses on the development and commercialisation of generic injectable and speciality pharmaceutical products and has built strategic partnerships with leading manufacturers over the years that have led to the distribution of products in over 60 global territories.
Cameron Mitchell, outgoing CEO of Synchrony Pharma commented: “It's been a pleasure working with the life sciences team at Stevens & Bolton. We particularly valued their depth of experience, insights and guidance on the M&A strategy and process, combined with invaluable life sciences expertise on regulatory and IP aspects.”
Keith Syson, Senior Partner at Stevens & Bolton said: “It was a pleasure to work with Cameron and his team to bring about this successful exit and we wish them well in their new venture.”
The Stevens & Bolton team was led by corporate partner Keith Syson, together with Charlotte Lane and Edward Cummings (corporate), Charlotte Tillett and Melissa Turner (intellectual property), Gustaf Duhs (regulatory), Michelle Hobbs (employment) and Beverley Flynn (commercial).